Home › Lung Cancer › Texas
Lung Cancer clinical trials in Texas
101 studies for Lung Cancer are looking for participants at sites in Texas.
Cities in Texas
- Houston78 studies
- San Antonio27 studies
- Dallas26 studies
- Austin6 studies
- League City6 studies
- Sugar Land6 studies
- Fort Worth6 studies
- The Woodlands6 studies
- Irving5 studies
- Amarillo5 studies
- Tyler4 studies
- El Paso4 studies
- Richardson3 studies
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Oncology Consultants PA, Houston
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 13, 2026 · NCT05920356A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07063745Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Texas Oncology - DFW ( Site 8003), Dallas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT06780098Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity
- The University of Texas M. D. Anderson Cancer Center, Houston
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06909201Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- University of Texas MD Anderson Cancer Center, Houston
- Local Institution - 0173, San Antonio
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07100080This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- The University of Texas, MD Anderson Cancer Center - Woodlands, Conroe
- Renovatio Clinical - El Paso, El Paso
- The University of Texas MD Anderson Cancer Center Diagnostic Imaging, Houston
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06758401Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Hendrick Medical Center, Abilene
- Houston Methodist San Jacinto Hospital, Baytown
- Parkland Memorial Hospital, Dallas
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04267848Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- Audie Murphy VA Medical Center, San Antonio
- Brooke Army Medical Center, San Antonio
Recruiting
Ages 50 to 80 · All sexes · Updated Nov 12, 2026 · NCT07168993Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- and 2 more
RecruitingPhase 3
Ages 70 and older · All sexes · Updated Nov 12, 2026 · NCT06096844A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, Fort Worth
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07099898Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- The University of Texas Southwestern Medical Center at Dallas, Dallas
- Renovatio Clinical - El Paso, El Paso
- JPS Health Network, Fort Worth
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06793215Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Houston Methodist San Jacinto Hospital, Baytown
- Houston Methodist Cypress Hospital, Cypress
- Parkland Memorial Hospital, Dallas
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT04181060A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06400472VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- The University of Texas MD Anderson Cancer Center (site 127), Houston
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Nov 4, 2026 · NCT03556228SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
- Mary Crowley Cancer Research, Dallas
- MD Anderson, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07857616A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07492680A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Texas Oncology, Austin
- William Beaumont Army Medical Center, Fort Bliss
- Houston Methodist Hospital, Houston
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06060613A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
- START San Antonio, LLC, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07903415Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Texas Oncology, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07185997Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
- University of Texas, MD Anderson Cancer Center, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07499674A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Houston
- Research Site #2, San Antonio
- Research Site, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06835569A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Recruiting
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT02984761Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Dallas, Irving
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06922591A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Texas Medical Branch, Galveston
- The University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Health, Temple
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07154290Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Houston
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Oct 21, 2026 · NCT05061550Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06810544Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06582017A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
- UT Health San Antonio, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06244771Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology Dallas, Irving
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06162221AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Dallas
- Avenzo Therapeutics Recruiting Site, Houston
- Avenzo Therapeutics Recruiting Site, San Antonio
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Oct 16, 2026 · NCT07038343Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology Cancer Center, Sugar Land
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06712355Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05786924Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Start - Dfw, Fort Worth
- Oncology Consultants, Houston
- START - San Antonio, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- The Don and Sybil Harrington Cancer Center, Amarillo
RecruitingPhase 2
18 Minutes · All sexes · Updated Oct 9, 2026 · NCT06031688From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.